Clinical Trial Update: Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating olaparib in combination with durvalumab and UV1 for relapsed ovarian cancer; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Lynparza (olaparib)
• UV1

Snippet

Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Conditions: Ovarian Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING